Search
lanadelumab (Takhzyro)
Indications:
- hereditary angioedema
Dosage:
- twice monthly SQ
Mechanism of action:
- monoclonal antibody inhibitor of kallikrein
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
hematologic agent
References
- Amrol DJ
Novel Medication for Hereditary Angioedema
NEJM Journal Watch. Feb 23, 2017
Massachusetts Medical Society
(subscription needed) http://www.jwatch.org
- Banerji A, Busse P, Shennak M et al.
Inhibiting plasma kallikrein for hereditary angioedema
prophylaxis.
N Engl J Med 2017 Feb 23; 376:717.
PMID: 28225674
http://www.nejm.org/doi/10.1056/NEJMoa1605767